Zacks Investment Research upgraded shares of SIMULATION PLUS (SLP) from NEUTRAL to OUTPERFORM on October 27, 2014, with a target price of $7.20.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SIMULATION PLUS (SLP),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment